Офтагель

Quick links to important sections

Офтагель

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Офтагель

Quick Facts

Property Description
Active Ingredient Carbomer (Polyacrylic acid)
Form Eye gel (Ophthalmic gel)
Pharmacological Class Ocular lubricant, Keratoprotector
Common Use Tear fluid deficiency
Origin Synthetic polymer

What Type of Ophthalmic Preparation is Офтагель?

Офтагель (Oftagel) is an ophthalmic preparation classified primarily as an ocular lubricant and a keratoprotector, utilized for the management of surface moisture deficiencies in the eye. Its pharmacological identity places it within the therapeutic group of artificial tear substitutes designed to stabilize and sustain the integrity of the cornea. This medicine acts as a keratoprotector, supporting the maintenance of the eye's protective surface.

This preparation serves a mechanical function by compensating for insufficient or unstable natural tears, a scenario common in conditions like dry eye syndrome. As a monocomponent medicine, its general therapeutic purpose is defined by its physical properties, focusing entirely on providing sustained hydration and protection to the eye's outer layers. Офтагель is typically available as an over-the-counter (OTC) medicine, making it readily accessible for common tear fluid deficiency.


Composition and Origin: Is Carbomer Synthetic?

The active ingredient in Офтагель is Carbomer (Polyacrylic acid), a synthetic polymer that is responsible for the formulation's necessary viscosity. Carbomer is a high molecular weight compound, widely employed in pharmaceutical products as an excipient for thickening and gelling.

Unlike conventional liquid drops, the medicine is supplied as an eye gel (ophthalmic gel), which is the most distinguishing feature of its dosage form. The synthetic polymer composition allows the preparation to achieve significant viscosity enhancement compared to lower-viscosity solutions. Carbomer formulations function as efficient tear substitutes by increasing the residence time on the eye. This means the gel stays in contact with the eye longer, offering extended protection and lubrication.


General Purpose: What Does Офтагель Help to Relieve?

The primary therapeutic goal of Офтагель is to relieve the physical discomforts associated with inadequate tear production, notably dry eye syndrome (keratoconjunctivitis sicca). The gel formulation's physiological action is to facilitate tear film stabilization and corneal hydration, which are the key general benefits.

This formulation effectively mitigates the common symptoms of dryness, burning, and the uncomfortable sensation of a foreign body on the ocular surface. The Carbomer-based gel works by reducing discomfort and improving the stability of the precorneal tear film in patients with dry eye. This supports the role of the medicine in improving the quality of the tear film and supporting the health of the keratoprotector surface.

What side effects are possible with Офтагель?

Possible Side Effects and Safety Information

The safety profile of Офтагель (Carbomer ophthalmic gel) is primarily characterized by localized effects related to its physical properties, consistent with regulatory information from authorities like the EMA and FDA.


Documented Adverse Reactions

Adverse reactions are classified based on frequency observed in clinical studies and post-marketing surveillance:

Frequency Classification Common Adverse Reactions
Very Common (ge 1/10) Vision blurred (transient)
Common (1/100 to <1/10) Ocular discomfort, eye irritation, eyelid margin crusting
Uncommon (1/1,000 to <1/100) Eye pain, eye pruritus, ocular hyperaemia (redness), increased lacrimation, periorbital oedema

These effects are largely confined to Eye disorders and are generally transient. Due to the high molecular weight of the active ingredient, Carbomer, systemic absorption is considered negligible, meaning systemic side effects in other organ systems are not documented in product labeling.


High-Level Safety Considerations

Regulatory documentation notes that the blurred vision is explicitly transient and occurs immediately following application due to the gel's viscosity, reflecting a time-related safety pattern.

The most important safety restriction is the contraindication against use in individuals with known hypersensitivity to the active substance or any excipients. Furthermore, while the frequency is considered Not Known or rare, the possibility of severe hypersensitivity reactions (allergic reactions) remains a documented serious adverse reaction.

Regulatory assessments state that effects during pregnancy and lactation are not anticipated because of the negligible systemic exposure.

Overdose and Emergency Response

Official Overdose Profile and Action Required

The official regulatory documents concerning Carbomer (Polyacrylic acid) ophthalmic gel establish a low-risk profile regarding overdose and toxicological events. Government-authorized prescribing information, such as that within the European framework, indicates that no toxic effects are expected following an ocular overdose of the preparation or in the event of accidental ingestion of the contents.

This classification is grounded in the pharmacological profile of the active ingredient. Due to its high molecular weight, systemic absorption or accumulation in systemic tissues is precluded, meaning the potential for systemic toxicity is negligible. For this reason, the overdose scenario is frequently classified in regulatory texts as "Not relevant" or "Not applicable" [SmPC Documentation].

As toxicological effects are not anticipated, regulatory labels typically do not mandate specific urgent help-seeking actions for overdose. Instead, the official guidance specifies that should any untoward or non-toxic effects be experienced after excessive application, the resulting discomfort should be addressed with symptomatic and supportive treatment. No population-specific monitoring or severe outcome considerations are documented in the official overdose sections.

Therapeutic Uses of Офтагель

What Офтагель treats: Main Uses and Benefits

Офтагель is commonly used across two primary therapeutic domains, providing necessary support for the ocular surface in contexts of deficient natural tear function. The preparation is utilized for the symptomatic treatment of dry eye.

Addressing Symptoms of Chronic Dry Eye and Surface Irritation

This preparation is primarily utilized for the symptomatic treatment of conditions like Dry Eye Syndrome (DES) and Keratoconjunctivitis Sicca (KCS), which are conditions where functional stability becomes affected. It is commonly used to help with the persistent symptoms related to physical discomfort, including the feelings of burning, stinging, and scratchiness, alongside the irritating foreign body sensation. This contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Support for Ocular Lubrication and Visual Function

Офтагель is considered relevant in clinical scenarios where supportive symptomatic assistance is needed for the eye's outer layer. It is applied across domains where additional symptomatic support is needed, and may assist with addressing dryness-induced visual disturbances, such as intermittent blurry or 'filmy' vision. This provides supportive therapeutic benefit, helping patients cope more steadily with symptom fluctuations in contexts like post-operative care or during periods of environmental stress.


Quick Fact: Relief for Persistent Dryness

Офтагель is specifically used when symptoms create noticeable physiological strain, offering sustained support for chronic conditions that involve significant physical discomfort and symptoms that interfere with daily functioning.

Eligibility and Restrictions for Use

Official Eligibility Profile for Офтагель (Carbomer)

Eligibility Status Applicable Population Regulatory Basis
Contraindicated Individuals with known hypersensitivity to the active substance (carbomer) or any of the product's excipients. Exclusion from Use
Conditional Use Soft Contact Lens Wearers must remove lenses before application. Excipient (Preservative) Risk
Conditional Use Pregnant or Breastfeeding Women; use is not recommended except for compelling reasons. Lack of Clinical Trial Data
Conditional Use Children and Adolescents (up to 18 years); use is based on clinical experience. Lack of Clinical Trial Data

The official regulatory documentation for Офтагель (carbomer eye gel) primarily restricts use based on a key contraindication: known allergy to any component of the formulation. Use in soft contact lens wearers is permitted, but is subject to the restriction of removing the lenses for at least 15 minutes due to the preservative. For both pediatric patients and those who are pregnant or breastfeeding, the eligibility status is conditional because formal clinical trials establishing safety and efficacy in these specific populations are currently unavailable in the regulatory evidence base.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products: Official Regulatory Information

The official interaction profile for Офтагель (Carbomer eye gel) is focused exclusively on topical physical interactions and administration timing rules, reflecting the drug’s negligible systemic absorption. Systemic interactions, such as those involving CYP enzymes or drug transporters, are not expected or documented in regulatory prescribing information.


Documented Interaction Constraints

Category Officially Documented Constraint
Interacting Product Class Other Ophthalmic Preparations (e.g., eye drops, ointments)
Interaction Mechanism Modification of Ocular Residence Time (Pharmacodynamic/Physical)
Administration Timing Rule Офтагель must always be the last eye medication instilled.

The gel's high viscosity can prolong the ocular residence time of other topically applied medicines, which is the documented basis for the timing requirement. Regulatory guidelines mandate a separation interval of at least five to fifteen minutes after any other eye drops are administered before the gel is applied. This rule ensures the efficacy of the preceding topical medication.

Product Restriction: A procedural restriction, documented in the labeling, requires that contact lenses must be removed prior to application. Lenses may be reinserted 30 minutes after instillation to prevent interaction with the preservative.

Mechanism of Action

How Oftagel Works: Mechanism of Action


Viscosity Modulation and Hydrogel Formation

Oftagel's mechanism is purely biophysical, focusing on modifying the physical properties of the tear film. Upon contact with the ocular surface, the acidic Carbomer 974P polymer neutralizes due to the tear's pH. This pH-dependent change causes the high-molecular-weight polymer chains to uncoil and swell, resulting in the formation of a cohesive, thickened hydrogel matrix. This action targets the aqueous layer and contributes to increased structural integrity of the tear film and resistance to mechanical shear forces.


Sustained Ocular Surface Adhesion and Evaporative Control

This hydrogel exhibits mucoadhesion, a physical adherence mechanism achieved through non-covalent bonding between the polymer structure and the mucin layer on the conjunctival and corneal epithelia. The resulting physical interaction leads to prolonged retention of the polymer on the ocular surface, modifying the typical rate of pre-corneal clearance. Additionally, the layer acts as a mechanistic barrier at the air-tear interface, modulating the rate of solvent loss and thereby influencing the osmolarity of the tear film, limiting the physical drivers that lead to increased tear film hyperosmolarity.

Dosage and Administration Information

Instruction Map: How to use Офтагель

This content describes the general patterns for the use of Carbomer eye gel (such as Офтагель), adhering to the principles of high-level, non-instructional usage descriptions.


Administration Scope

Feature Guideline
Route of administration Ocular (topical instillation).
Dosing schedule Instill one drop into the affected eye(s) per application.
Frequency and timing Highly variable, often ranging from 3 to 5 times daily, or as required based on symptomatic need.
Age-group administration rules Older Adults: No dosage amendment is necessary. Children and Adolescents: The standard adult posology is generally applied, based on clinical experience.
Special procedural conditions The gel must be the final ophthalmic preparation instilled, with a 15 minute interval after any preceding eye drops.

Resulting Procedural Structure

The procedure for Carbomer eye gel ensures maximum contact time on the ocular surface:

  • Remove soft contact lenses prior to the administration of the gel.
  • Instill one drop into the inferior conjunctival cul-de-sac (the fold below the lower eyelid).
  • If other ophthalmic drops are used, ensure the gel is instilled at least 15 minutes after the other preparation.
  • Do not allow the container tip to touch the eye or any surrounding structures to maintain product sterility.
  • Reinsert contact lenses only after 15 to 30 minutes have elapsed following the gel instillation.

Connection to the overall use protocol:

The use protocol for this ophthalmic gel is defined by its fixed unit dose and its topical ocular route of administration. The frequency is determined by the patient's symptomatic need, supporting its intended role as a sustained therapy without a fixed maximum duration. The critical procedural constraint is the sequencing rule, which prevents the application of less viscous preparations from immediately removing the gel, thereby maintaining its presence on the ocular surface for the stated time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Офтагель

This overview summarizes the research that was evaluated for the active ingredient in Офтагель (Carbomer/Polyacrylic Acid Eye Gel). It describes the types of studies available, what they measured, and what remains uncertain, without providing any clinical advice or specific recommendations.


1. Evidence for Symptomatic Relief in Dry Eye Syndrome

The primary research focus for this medicine was studied for its use in contexts related to Dry Eye Syndrome (DES) and a similar condition, Keratoconjunctivitis Sicca (KCS). The evidence base includes several Randomized Controlled Trials (RCTs), some of which were placebo-controlled or compared the gel to other common eye drop formulations. These studies were used in research exploring how symptoms change over time in adult patients.

Studies examined outcomes related to physical discomfort, focusing primarily on patient reports of the frequency and severity of feelings such as burning, scratchiness, stinging, and the sensation of a foreign body. The findings describe patterns observed in the studies where participants reported change in their subjective discomfort scores during the study period.


2. Research on Ocular Surface Integrity and Tear Film Stability

Research has specifically examined the objective measures of the preparation's keratoprotector action, including studies that assessed Tear Break-Up Time (TBUT) and changes in corneal/conjunctival staining scores. Findings indicate that the gel data showed patterns related to TBUT and surface staining scores during the study period.

Evidence in Specific Patient Populations

The existing research has primarily focused on adult patients with dry eye conditions. Data for certain groups remain insufficient. Clinical trial data are limited for the use of this gel in children and adolescents. Research has not fully established patterns of use or outcomes in these younger populations.


3. What Remains Uncertain About Офтагель Research

The evidence highlights what is known—and what is still uncertain. Most foundational evidence comes from short-term clinical trials, and long-term effects are not fully established through extensive randomized controlled research. Additionally, the sample sizes were modest in some pivotal trials, meaning the findings describe group patterns, not personal outcomes. The research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Офтагель (FAQ)


Q: How does Офтагель compare to other common eye drops for dryness?

Regulatory documents indicate that this gel preparation is formulated for extended contact time compared to standard liquid eye drops. The higher viscosity of the gel is described as contributing to the structural integrity of the tear film and prolonged retention on the eye surface.


Q: How long does the effect of one application of Офтагель usually last?

Studies and official information state that the gel's physical presence on the eye surface persists for approximately 30 minutes following instillation. Clinical data suggest that tear film stability, an objective measure, showed patterns related to maintenance for a period of up to 6 hours in studies.


Q: What happens if I accidentally use Офтагель more often than stated on the packaging?

According to official product information, toxic effects are not anticipated from an ocular overdose of the gel. This is attributed to the eye's limited capacity for absorption. Similarly, accidental oral ingestion of the contents of one bottle is also not expected to result in toxic effects.


Q: What are the ingredients in Офтагель?

The active ingredient in Офтагель is Carbomer 974P. Official labeling lists several other components, known as excipients, which help create the gel structure. This preparation also includes a preservative, such as benzalkonium chloride (or similar, depending on the formulation). The preservative is the element that necessitates specific guidance regarding contact lens use.


Q: Are there any known issues with using Офтагель with lubricating ointments?

Official regulatory guidelines define ophthalmic ointments as 'other eye preparations' in the context of interactions. Regulatory documents specify a timing requirement: the gel is intended to be instilled last among ophthalmic preparations. A separation interval of at least 5 to 15 minutes is mandated after the preceding product.


Q: Can people who have had eye surgery use Офтагель?

Regulatory documents do not list prior eye surgery as a general contraindication. However, post-market safety data has, at times, led to temporary advisories for cautious use of carbomer-containing gels in patients with specific, severe health risks or those in critical care settings. Known allergy to any component remains the only formal contraindication.


Q: Is there a maximum number of times per day Офтагель is generally used?

The recommended frequency described in regulatory documents is up to 4 times a day (or 1 to 4 times daily), or as required based on the degree of ocular trouble. The frequency is determined by the official prescribing information.


Q: What should I do if my eye irritation seems worse after using Офтагель?

Regulatory information notes that if symptoms of ocular discomfort or irritation persist or worsen, or if severe hypersensitivity occurs, discontinuation of the product is advised in the labeling. Worsening irritation may be a sign of a rare, but documented, serious adverse reaction.


Q: Why do official sources sometimes call it Carbomer 974P eye gel?

The active ingredient is formally known as Carbomer, but 974P is the specific designation or grade of the polymer used in the formulation. This particular grade of polyacrylic acid is selected for its characteristics, which are necessary to achieve the desired viscosity and sustained retention time on the eye surface.


Q: Can I use Офтагель while driving?

Official safety information includes a specific warning about the ability to drive. Because the gel can cause temporary blurred vision immediately after instillation, patients who experience blurred vision are directed to wait until their vision clears before resuming activities like driving or operating machinery.


Q: Can men and women use Офтагель in the same way?

Yes. Regulatory documents confirm that there are no gender-specific restrictions, dosage differences, or known variations in how the medication acts in men versus women. The official instructions for use apply equally to all adults.


Q: Is it normal for the gel to feel thick when applied?

Yes, a thick feeling upon application is consistent with the product's design. The gel works by forming a highly viscous, thickened film on the eye surface. This increased viscosity is the intentional mechanism that helps prolong the gel's contact time compared to standard drops.


Q: Can I use Офтагель if I have other pre-existing eye conditions?

Regulatory documentation only lists known hypersensitivity to any ingredient as a formal contraindication. For all other conditions, official safety updates have advised temporary caution in individuals with specific, severe health issues (e.g., cystic fibrosis, severely immunocompromised) due to contamination risks.


Q: Can the product be used by people with sensitive eyes?

Regulatory data classifies the gel as having a low potential for toxicity and irritation. However, mild and transient irritation or ocular discomfort is explicitly listed as a common side effect observed during clinical trials. Hypersensitivity (allergy) to the product remains the only official contraindication.


Q: Can I use Офтагель for eye fatigue?

Official product information indicates that the product is intended solely for the symptomatic treatment of conditions related to tear film deficiencies, such as dry eye syndrome. The product is not listed for the relief of general eye fatigue.


Q: Does Офтагель contain any animal-derived ingredients?

The active ingredient, Carbomer (Polyacrylic acid), is a synthetic polymer. Since systemic absorption is negligible, the interaction profile is minimal. Regulatory documentation for the excipients, such as the preservative, does not indicate the presence of animal-derived components.


Q: Are there any dietary restrictions associated with using Офтагель?

No. Due to its very low systemic absorption, official regulatory documents state that the product has no known clinically relevant interactions with food or other systemic (oral) products.

How should Офтагель be stored and disposed of?

How to Store and Dispose of Офтагель?

Strict storage and disposal requirements for this medicine are defined by regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Condition Regulatory Specification
Temperature Store in a refrigerator (2°C to 8°C). Do not freeze.
Protection Keep the bottle in the outer carton to protect from light.
Child Safety Keep this medicine out of the sight and reach of children.

Stability and Disposal

Condition Regulatory Specification
In-Use Stability The bottle must be discarded 28 days after first opening.
Disposal Do not dispose of via wastewater or household waste. Ask your pharmacist about proper disposal methods for medicines no longer needed to help protect the environment.

These official rules define the product's storage environment as cool and protected from both freezing and light, and mandate discarding the product within 28 days of first use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Офтагель found in:

A-Z Index: